“The Impentri IMI2 consortium are pleased to announce the first patients have been dosed in Amsterdam, NL as part of its clinical trial to investigate the safety and efficacy of intravenous imatinib mesilate (Impentri™) in subjects with Acute Respiratory Distress Syndrome induced by COVID-19”
The trial is a Phase II, randomised, double-blind, placebo-controlled study being conducted at clinical centres in The Netherlands, enrolling 90 COVID-19 patients with moderate to severe ARDS and who are intubated for mechanical ventilation. This trial follows the successful completion of a Phase II study of orally administered imatinib in 386, COVID-19 infected and hospitalised patients with hypoxaemia, conducted at 10 clinical sites across The Netherlands. Details of the new trial can be found on the European Clinical Trials register [EudraCT number: 2020-005447-23].
Impentri™, a reformulation of exisiting therapy, imatinib has been developed and manufactured at KABS in Canada, and patients are initially being enrolled at the Vrije Universitat and Amsterdam Medical Centers. The trial is being managed by Simbec-Orion, based in France.